Prognostic nomogram of xerostomia for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy.


Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
31 01 2020
Historique:
received: 13 09 2019
accepted: 02 01 2020
pubmed: 1 2 2020
medline: 9 1 2021
entrez: 1 2 2020
Statut: ppublish

Résumé

Xerostomia is a common radiation-induced late complication after radiotherapy. Identifying predictive factors for xerostomia will lead to better treatments and improve the quality of life. This study was conducted to establish an effective predictive nomogram for xerostomia by assessing stage I-IVb (AJCC 7th edition) NPC patients between September 2015 and March 2016. Xerostomia was evaluated via the RTOG/EORTC system. The primary endpoint was grade 2-3 xerostomia 1 year after treatment. The predictive factors for xerostomia were analysed using logistic regression analysis. A nomogram was constructed based on combining the predictors and clinical variables. In total, 102 patients with grade 0-1 xerostomia and 93 patients with grade 2-3 xerostomia were included. The independent predictive factors for xerostomia were V25, V30, V35, and V45 of the ipsilateral parotid gland and mean dose of the contralateral parotid gland. The calibration plot for the probability of xerostomia showed good agreement between prediction by the nomogram and actual observation. The concordance index of the nomogram for predicting xerostomia was 0.796 (95% CI: 0.735-0.857, P <0.001), which was higher than any single dosimetric parameter. Our results indicated that the nomogram provided a more accurate prediction of grade 2-3 xerostomia 1 year after treatment.

Identifiants

pubmed: 32005029
pii: 102717
doi: 10.18632/aging.102717
pmc: PMC7053606
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1857-1866

Références

J Clin Oncol. 2015 Oct 10;33(29):3322-7
pubmed: 26351336
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Radiat Oncol. 2015 Jan 13;10:17
pubmed: 25582731
Radiother Oncol. 2014 Mar;110(3):398-403
pubmed: 24231245
Curr Oncol Rep. 2005 Mar;7(2):131-6
pubmed: 15717947
Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):445-53
pubmed: 16839705
Br J Cancer. 2014 Jan 7;110(1):49-54
pubmed: 24253503
Oral Oncol. 2016 Feb;53:67-73
pubmed: 26675283
Jpn J Clin Oncol. 2006 Oct;36(10):626-31
pubmed: 17008345
Radiother Oncol. 2019 Sep;138:149-157
pubmed: 31265972
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1055-69
pubmed: 15990009
Biomed Res Int. 2014;2014:814948
pubmed: 25162028
Radiother Oncol. 2013 Mar;106(3):346-51
pubmed: 23540553
Radiat Oncol. 2011 Sep 27;6:125
pubmed: 21951317
Head Neck. 2006 Aug;28(8):712-22
pubmed: 16475203
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Radiother Oncol. 2012 Sep;104(3):286-93
pubmed: 22995588
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87
pubmed: 10524409
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):61-70
pubmed: 12909216
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):660-9
pubmed: 17141973
Cancer. 2004 Oct 1;101(7):1584-93
pubmed: 15378492
Chin J Cancer. 2011 Feb;30(2):114-9
pubmed: 21272443
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Oral Oncol. 2012 Sep;48(9):864-9
pubmed: 22445296
J Radiat Res. 2016 Aug;57 Suppl 1:i69-i75
pubmed: 27538846
Oral Oncol. 2013 Feb;49(2):175-81
pubmed: 23021729
Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704
pubmed: 11395238
Oncotarget. 2016 Apr 19;7(16):21742-52
pubmed: 26942881
Oncotarget. 2017 Apr 27;8(44):78096-78104
pubmed: 29100451
Radiother Oncol. 2002 May;63(2):203-11
pubmed: 12063010
Oncotarget. 2017 Feb 21;8(8):14029-14038
pubmed: 28152511
Oral Oncol. 2013 Jan;49(1):42-8
pubmed: 22854066
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S58-63
pubmed: 20171519
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):340-352
pubmed: 30191868

Auteurs

Xin-Bin Pan (XB)

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China.

Yang Liu (Y)

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China.

Ling Li (L)

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China.

Song Qu (S)

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China.

Long Chen (L)

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China.

Shi-Xiong Liang (SX)

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China.

Kai-Hua Chen (KH)

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China.

Zhong-Guo Liang (ZG)

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China.

Xiao-Dong Zhu (XD)

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH